Skip to main content

SYSTEMATIC REVIEW article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1341631
This article is part of the Research Topic Allogenic Hematopoietic Cell Transplant in Hematological Malignancies: Controversies and Perspective View all 10 articles

Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in recent ten years

Provisionally accepted
SiYu Lin SiYu Lin KeJie Lu KeJie Lu XiaoNa Zheng XiaoNa Zheng Jian Hou Jian Hou Tingting Liu Tingting Liu *
  • Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

The final, formatted version of the article will be published soon.

    Allogeneic hematopoietic cell transplantation (alloHCT) possessed direct cytotoxicity and graft-versus-multiple myeloma effect (GvMM). Growing trials have shown survival benefits of performing alloHCT in both newly diagnosed and relapsed MM. We aimed to provide a comprehensive analysis among the recent ten years to verify the efficacy and survival outcome of alloHCT in MM patients. 61 Studies which provide data between 14 April 2013 to 14 April 2023 and a total of 15294 data from MM patients who had undergone alloSCT were included in our study. Best response rates (CR, VGPR, PR) and survival outcomes (1,2,3,5,10 year-OS, PFS, NRM) were assessed. The pooled estimate CR, VGPR and PR rate was 0.45, 0.21 and 0.24 respectively. The pooled estimate of 1, 2, 3, 5, 10-year OS was 0.69, 0.57, 0.45, 0.45, 0.36 respectively; the pooled estimate of 1, 2, 3, 5, 10-year PFS was 0.47, 0.35, 0.24, 0.25, 0.28 respectively; the pooled estimate of 1, 2, 3, 5, 10-year NRM was 0.16, 0.21, 0.16, 0.20, 0.15 respectively. Our results showed constant OS, PFS, and NRM from third year onwards till the tenth year, suggest that alloSCT has sustained survival benefits.We further conducted meta-analysis in NDMM/frontline setting and RRMM/salvage setting independently. In NDMM/upfront setting, the pooled estimate CR rate was 0.54, 5-year OS, PFS, NRM was 0.69, 0.40, 0.11 respectively. In relapsed setting, the pooled estimate CR rate was 0.31, 5-year OS, PFS, NRM was 0.24, 0.10, 0.15 respectively. Good response rate and promising survival outcome was observed in NDMM/frontline setting.Although comparing with other treatments, alloSCT had a lower response rate and poorer short-term survival outcome, long-term follow-up could reveal survival benefits of alloSCT in MM patients.

    Keywords: Multiple Myeloma, allogeneic stem cell transplantation, response rate, Survival outcome, os, PFS

    Received: 20 Nov 2023; Accepted: 09 Jul 2024.

    Copyright: © 2024 Lin, Lu, Zheng, Hou and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Tingting Liu, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200000, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.